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e under theAbstract Aim: This study sought to determine knowledge of and attitude towards
human papillomavirus (HPV) infection, HPV-related diseases and HPV vaccines
among female undergraduate students at the University of Lagos.
Methods: A self-administered questionnaire was administered between May and
July 2010, to 368 female students aged 16–29 years, who were selected from two
faculties of the University of Lagos using two-stage sampling method. Data collected
included: socio-demographic characteristics, sexual history, awareness and knowl-
edge of HPV infection, cervical cancer and genital warts, and HPV vaccine; the per-
ceived risk of acquiring genital HPV infection and developing cervical cancer or
genital warts, and the willingness to receive an HPV vaccine.
Results: Only 64 (17.7%) and 52 (14.4%) of the students had ever heard of HPV
infection and HPV vaccines respectively. The median HPV knowledge on a 15-item
score was 2. Overall, only 11.1% knew that genital HPV infection can cause cervical2
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200 C.C. Makwe et al.cancer. Fourteen (6.9%) of those who were aware of cervical cancer agreed they
were at risk of developing the disease. Of the 52 students who had heard of the
HPV vaccine, 24 (46.2%) knew it was given for cervical cancer prevention and 30
(57.7%) expressed their willingness to receive the vaccine.
Conclusion: The knowledge of and the perceived susceptibility to HPV infection
and HPV-related diseases among female students in the University of Lagos were
generally low. The need for a well-designed HPV-educational program to bridge
the knowledge gap cannot be overemphasized.
ª 2012 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Genital human papillomavirus (HPV) infection is
one of the most common sexually transmitted
infections (STI) [1]. About 50–80% of sexually ac-
tive women are exposed to at least one HPV type
during their lifetime [2]. The peak incidence of
HPV infection occurs in most populations within
5–10 years of the first sexual experience and the
highest prevalence rates are seen in women aged
20–24 years [3,4]. Individual and group sexual
behaviours are important in HPV transmission [5].
The transmission of genital HPV infection is influ-
enced by age at sexual debut, number of sexual
partners and acquisition of new partners, charac-
teristics of partners and sexual networks, concur-
rency and serial monogamy [6]. The persistent
infection with specific types of HPV is associated
with the development of HPV-related diseases
(non-malignant and malignant) [7].
Cervical cancer is the commonest gynaecologi-
cal cancer in women worldwide. More than 85% of
the global burden occurs in developing countries
where it accounts for 13% of all female cancers
and a major cause of cancer-related deaths [8].
There are specific high-risk HPV types associated
with cervical cancer. About 70% of cervical cancer
is caused by HPV type 16 and 18 [9]. Genital warts
are benign growths that are most often caused by
certain low-risk types of HPV [10]. More than 90%
of genital warts are related to low-risk HPV type
6 and 11 [10].
Two HPV vaccine types are now available for the
prevention of HPV-related diseases. The quadriva-
lent vaccine targets HPV types 6, 11, 16 and 18,
and the bivalent vaccine targets HPV types 16 and
18. Both the quadrivalent and the bivalent vaccines
have a high efficacy against HPV types 16- and 18-
related cervical intraepithelial neoplasia (CIN) and
cervical cancers. The HPV vaccine was licensed in
Nigeria in 2008.
University students and young adults have a high
prevalence of genital HPV infection because of
their risky sexual behaviour, lack of knowledge ofHPV infection and HPV-related diseases, and mis-
conception about susceptibility [11,12]. Studies
conducted among university and college students
have shown that the awareness of genital HPV
infection ranges from 13% to 78% [11–18], while
the awareness of the HPV vaccines ranges from
10% to 87% [16,19–21]. The perceived risk among
students of acquiring genital HPV infection ranges
from 12.7% to 42% [15,22,23] and of developing
cervical cancer ranges from 19.9% to 68%
[18,22,23].
A recent search of the literature found only one
study on the knowledge of genital HPV infection
and the attitude towards HPV vaccination among
university students in Nigeria [24]. The study was
conducted in northern Nigeria. The objective of
this study was to assess the knowledge of HPV
infection and the HPV vaccine among female
undergraduate students in the University of Lagos,
South-West Nigeria, and their attitude towards
HPV-related diseases and HPV vaccination.
2. Materials and methods
2.1. Setting
This cross-sectional descriptive study was con-
ducted at the University of Lagos between 30th
May and 29th July 2010. The University of Lagos
has nine faculties, a college of medicine and a
school of post-graduate studies. The University
had 8356 full-time, female, undergraduate stu-
dents who registered for the 2009/2010 academic
year.
2.2. Study design and sample
The minimum sample size was calculated using a
formula for finite population and adjusted for
anticipated non-response by 10%. Assuming 50% of
the students had sufficient knowledge about HPV
infection, a random sample of 398 female under-
graduate students was selected using a two-stage
sampling technique with 95% confidence and 5%
Table 1 Sociodemographic characteristics.
Variable N = 362
n(%)
Mean
(SD)
Age (years) 21.5 (3.0)
16–20 152 (42.0)
21–25 172 (47.5)
26–30 38 (10.5)
Academic year of study
1 80 (22.1)
2 186 (51.4)
3 32 (8.8)
4 64 (17.7)
Faculty
Education 234 (64.6)
Social sciences 128 (35.4)
Marital status
Single 338 (93.4)
Married 24 (6.6)
Religion
Christianity 306 (84.5)
Islam 56 (15.5)
FDR who is a healthcare
providera
138 (38.0)
Sexually active 150 (41.4)
Age at first intercourse
(years)
19.8 (2.9)
Number of lifetime
sexual partners
1.97 (1.37)
0 212 (58.6)
1 76 (21.0)
2 40 (11.0)
P3 34 (9.4)
a FDR = First degree relative.
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considered as the primary sampling units. The Fac-
ulty of Education and the Faculty of Social Sciences
were selected and the study participants were then
selected from a sample frame of full-time, under-
graduate, female students from these two faculties
using the simple random sampling technique.
The students were contacted and recruited
through their classrooms. They had group counsel-
ling. They were informed that participation in the
study was voluntary, and they had the option to
opt out of the study at any point. The objectives
of the study and the methods to be used were ex-
plained fully to the students, and they were also
assured of the confidentiality of the data that they
would provide.
2.3. Study instrument
A 51-item, self-administered, anonymous, pre-
tested, structured questionnaire with closed- and
open-ended questions was used to obtain data.
The questions were adapted and modified from
previous studies by Wong et al. [16] and Chan
et al. [25]. It was divided into three parts: the first
part determined socio-demographic characteris-
tics; the second part assessed awareness and
knowledge of HPV infection, HPV-related diseases
and HPV vaccine; and the third part determined
the attitude towards HPV-related diseases and
HPV vaccine.
Demographic characteristics and sexual history
were assessed using nine items. Information on
the awareness was assessed using four items with
yes–no responses. The knowledge of cervical can-
cer, genital warts, HPV infection and HPV vaccine
were assessed using 15 items with true/false/I do
not know responses. One point was given for each
correct answer and the points summed to create
a knowledge score. The possible knowledge score
ranged from 0 to 15 points; low knowledge score
was a score of 0–7, intermediate was 8–10 and
high was 11–15.
Four attitudes about HPV vaccine were assessed
based on the health belief model, i.e., health be-
liefs, perceptions of who should receive the vac-
cine, normative beliefs and intention to receive
the vaccine. The health belief model was measured
by seven items assessing the views and self-per-
ceived risk of HPV infection, cervical cancer and
genital warts. There were five items on perception
of who should receive the vaccine. Normative be-
lief was assessed by five items on the participants
belief in persons who are important to them, who
would approve of their receiving the HPV vaccine.
There was one question to assess their intentionto receive the vaccine. Responses to all attitudinal
variables were assessed using 5-point Likert-type
scales ranging from strongly agree, agree, neither
agree nor disagree, disagree, to strongly disagree.
A verbal consent was obtained before a student
was included in the study. The questionnaires were
given out in the classroom, by hand, to the partic-
ipants. They completed the questionnaires straight
away and returned them to one of the investigators
(C.C.M.). They were not given any financial or
material incentive. Institutional ethical approval
was obtained for the study.
2.4. Data analysis
Data were entered, processed and analysed using
the EPI-Info version 6.04 statistical package. The
analysis results of participants demographics and
baseline variables were summarized using descrip-
Table 2 Knowledge of HPV infection, HPV-related diseases and HPV vaccine.
Variables N = 362 Mean (SD)
Awareness Yes (%)
Ever heard of cervical cancer 204 (56.4)
Ever heard of genital warts 80 (22.1)
Ever heard of HPV infection 64 (17.7)
Ever heard of HPV vaccine 52 (14.4)
Correct response
Knowledge of cervical cancer (N = 204) n (%)
Cervical cancer is the most common cancer of the FRTa 136 (66.7)
Pap smear can prevent cervical cancer 26 (12.7)
Cervical cancer is caused by persistent HPV infection 40 (19.6)
Cervical cancer is related to sexual activity 74 (36.3)
HPV infection is the most common STI 16 (7.8)
There are specific HPV types that cause cervical cancer 20 (9.8)
Early onset of sexual debut increases risk of cervical cancer 58 (28.4)
Multiple sexual partners increase the risk of cervical cancer 90 (44.1)
Smoking increases the risk of cervical cancer 46 (22.5)
Knowledge of genital warts (N = 80)
Genital warts are transmitted by sexual intercourse 32 (40.0)
Proper use of condom reduces the risk of genital warts 36 (45.0)
There are specific HPV types responsible for genital warts 16 (20.0)
Knowledge of HPV vaccine (N = 52)
HPV vaccine should be given to prevent:
HPV infection 38 (73.1)
Cervical cancer 24 (46.2)
Genital warts 20 (38.5)
Knowledge score 2.48 (2.11)
Low 0–7 322 (90.0)
Intermediate 8–10 28 (7.7)
High 11–15 12 (3.3)
a FDR = First degree relative.
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tion) or median (range) for continuous variables
and percent for categorical variables. Comparisons
of categorical responses were evaluated using Chi-
square test. Statistical significance was assessed
using two-tailed tests with an alpha error level of
0.05. A p-value <0.05 was considered to be statisti-
cally significant.
3. Results
A total of 368 female students participated in the
survey and a response rate of 92.5% was achieved.
Data were complete for 362 respondents and these
were analysed. The mean age of participants was
21.5 ± 3.0 years. Most (51.4%) of the participants
were in their second year in the University.
3.1. Sexual history
Two hundred and twelve (58.6%) of the students
were not sexually active. The mean age at sexualdebut was 19.8 ± 2.9 years (range of 8–26 years)
for those who were sexually experienced. The life-
time number of sexual partners was 1–6 partners
with a median of one partner (mean = 1.97,
SD = 1.37) (Table 1).
3.2. Awareness and knowledge of HPV
infection, HPV-related diseases and HPV
vaccine
Of the participants, 214 (56.4%) were aware of cer-
vical cancer, 64 (17.7%) were aware of HPV infec-
tion and 52 (14.4%) were aware of HPV vaccine.
The median HPV knowledge on a 15-item score
was 2 with a range of 0–13 (mean = 2.48, SD =
2.11). Majority (90%) of the students had a low
knowledge score (Table 2). Overall, only 40
(11.1%) of the participants knew that persistent
genital HPV infection causes cervical cancer. Most
of those who had heard of cervical cancer were
not aware of its association with HPV infection,
sexual activity, age at sexual debut and multiple
Table 3 Attitude towards HPV infection, HPV-related diseases and HPV vaccines.
Variables Strongly/Somewhat agree
n (%)
Cervical cancer (N = 204)
I worry about having cervical cancer 60 (29.4)
Suffering from cervical cancer will affect my daily life 92 (45.1)
I am at risk of cervical cancer 14 (6.9)
Genital warts (N = 80)
I worry about having genital warts 30 (37.5)
Suffering from genital warts will affect my daily life 44 (55.0)
I am at risk of genital warts 10 (12.5)
HPV infection (N = 64)
I am at risk of genital HPV infection 4 (6.25)
HPV vaccines (N = 52)
HPV vaccine should be given,
To girls before they become sexually active 22 (42.3)
To boys before they become sexually active 22 (42.3)
To all sexually active females 30 (57.7)
To all sexually active males 30 (57.7)
Only to individuals who have multiple sexual partners 10 (19.2)
HPV vaccine
I am willing to receive the HPV vaccine 30 (57.7)
Who will you seek approval from before receiving the HPV vaccine?
I will seek the opinion of my healthcare provider 48 (92.3)
I will seek the opinion of my mother 26 (50.0)
I will seek the opinion of my sister/brother 20 (38.5)
I will seek the opinion of my father 12 (23.1)
I will seek the opinion of my friends 6 (11.5)
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could be prevented by Pap smear (Table 2). Less
than 50% of students who were aware of HPV vac-
cine knew it is for prevention of cervical cancer
(Table 2); 40 (76.9%) out of the 52 students who
were aware of the HPV vaccine felt their self-as-
sessed knowledge of the vaccine was not sufficient,
while only 2 (3.9%) of them felt their knowledge
was sufficient.
3.3. Sources of HPV information
The most common source of information on HPV
infection and HPV vaccine was from television/
radio (21%), followed by print media (12.7%),
health campaigns (12.2%), family/friends (9.9%)
and healthcare providers (9.4%).
3.4. HPV-related beliefs and acceptance of
HPV vaccine
Of those who were aware of HPV infection, only
6.25% agreed (somewhat/strongly) that they could
be at risk of acquiring the infection, while 6.9% ofthose who had heard about cervical cancer agreed
they could be at risk of developing the disease
(Table 3). Of the 52 participants who had heard
about the HPV vaccine, 22 (42.3%) agreed it should
be given to girls before they become sexually
active and 30 (57.7%) agreed it should be given to
all sexually active females. More than half of the
students who had heard of the HPV vaccine stated
their willingness to be vaccinated and most
(92.3%) of them indicated that they would seek
the opinion of their healthcare providers before
receiving the vaccine (Table 3). Student level in
the University showed a significant association with
the awareness of HPV infection and HPV vaccine
(p-value < 0.001) (Table 4).
4. Discussion
This study showed a poor knowledge of genital HPV
infection and HPV vaccine among female under-
graduate students at the University of Lagos. Less
than one-fifth of the students had ever heard of
HPV infection. This is lower than what was ob-
tained in similar studies in Italy (23.3%) [22], Fin-
Table 4 Baseline characteristics as predictors of awareness of HPV infection and HPV vaccine.
Variable Awareness of HPV infection df X2 p-Value
Yes (n = 64) No (n = 298)
Age
16–20 24 128 2 0.00 0.974
21–25 36 136
26–30 4 34
Level (years)
First 4 76 3 22.42 <0.001
Second 32 154
Third 4 28
Fourth 24 40
FDR who is a healthcare provider
Yes 26 112 0.21 0.649
No 38 186
Sexual experience
Yes 30 110 2.20 0.138
No 34 188
Variable Awareness of HPV vaccine df X2 p-Value
Yes (n = 52) No (n = 310)
Age
16–20 20 132 2 0.14 0.709
21–25 30 142
26–30 2 36
Level (years)
First 6 74 3 13.90 <0.001
Second 22 164
Third 6 26
Fourth 18 46
FDR who is a HCP
Yes 24 114 1.66 0.197
No 28 196
Sexual experience
Yes 20 120 0.00 0.973
No 32 190
df = degree of freedom.
FDR = First degree relative.
HCP = Healthcare provider.
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(85%) [16]. The existence of comprehensive and
effective HPV educational programs in these coun-
tries may have resulted in a higher level of HPV
awareness. Most of the students in this study did
not know that HPV infection causes cervical can-
cer, despite the fact that more than half of them
had heard of cervical cancer. Overall, only 11.1%
of the respondents knew that genital HPV infection
causes cervical cancer. A study by Gerend et al.
[18] showed that over 90% of university students
correctly identified the association between HPV
and cervical cancer. Only 12.7% of the studentswho were aware of cervical cancer knew that Pap
smear test is for prevention of the disease. The
median HPV knowledge was 2, and this was rela-
tively lower than the score of 3–4 in similar studies
[15,16,18]. The poor knowledge of genital HPV
infection in spite of the relatively high cervical
cancer awareness may be due to insufficient infor-
mation on HPV in the various educational materials
used in cervical cancer awareness programs in
Nigeria.
The awareness of genital warts was very low
compared with 95.4% among first-year female col-
lege students in the United States [14]. It is also
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students who were aware of genital warts knew
that it is sexually transmitted.
Less than 10% of students who were aware of
HPV infection knew that they could be at risk of
getting infected. The poor knowledge of HPV infec-
tion and the low self-perceived susceptibility to
HPV infection and HPV-related diseases observed
in this study highlight the need for a well-designed
educational program on HPV infection in Nigeria.
Less than half of the students who were aware of
HPV vaccine agreed it is best given to girls before
sexual debut. Also, about three-fifths of the stu-
dents who were aware of the vaccine thought it
should be given to all sexually active females. This
is a reflection of their poor knowledge and/or mis-
understanding of genital HPV infection and HPV
vaccine. Both of the currently available HPV vac-
cines have been approved for the prevention of
cervical cancer and ideally should be given before
sexual debut.
About 60% of the students who were aware of
HPV vaccines expressed their desire to get vacci-
nated. A similar study in Italy [22] showed that
81.7% of respondents were willing to have the
HPV vaccine. The relatively higher level of vaccine
acceptance in Italy may be due to the impact of
HPV educational programs and the national HPV
immunization program, which offers free vaccina-
tions for girls aged 12 years. Interestingly, this
study showed that a significant proportion of the
students who were aware of the HPV vaccine would
seek the approval of their healthcare providers and
their mothers before receiving the vaccination.
This implies that the HPV educational programs in
Nigeria should target many population groups.
The main source of HPV information was televi-
sion/radio and this finding was consistent with sim-
ilar studies in Florida and Malaysia [18,27].
Television and radio are electronic mass media
commonly utilized by young adults for leisure and
entertainment, and could also be used to dissemi-
nate information on HPV infection and HPV
vaccine.
Student level in university had a significant asso-
ciation with the awareness of HPV infection and
HPV vaccine. A study in Brazil [23] showed that
respondents with higher educational attainment
were more likely to have a better knowledge of
HPV infection.
A potential limitation that should be considered
when interpreting this study is that the information
obtained was collected using a self-administered
questionnaire, and so the possibility exists that
some respondents may have given incorrect
information.5. Conclusion
The level of awareness and knowledge of genital
HPV infection and HPV vaccines among female
undergraduate students at the University of Lagos
was generally low. Their self-perceived susceptibil-
ity to HPV infection and HPV-related diseases was
also low. This study underscores the need to devel-
op a well-designed educational program on HPV in
Nigeria. The educational materials used for cervi-
cal cancer control and prevention programs in
Nigeria, should be updated to contain current sci-
entific knowledge on the causes and prevention
of cervical cancer.Acknowledgments
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